Diagnos Laboratorium Utama PT Tbk
IDX:DGNS
US |
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
|
US |
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
|
US |
Bank of America Corp
NYSE:BAC
|
Banking
|
|
US |
Mastercard Inc
NYSE:MA
|
Technology
|
|
US |
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
|
US |
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
|
US |
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
|
US |
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
|
US |
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
|
US |
Visa Inc
NYSE:V
|
Technology
|
|
CN |
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
|
US |
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
|
US |
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
|
US |
Coca-Cola Co
NYSE:KO
|
Beverages
|
|
US |
Walmart Inc
NYSE:WMT
|
Retail
|
|
US |
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
192
394
|
Price Target |
|
We'll email you a reminder when the closing price reaches IDR.
Choose the stock you wish to monitor with a price alert.
Johnson & Johnson
NYSE:JNJ
|
US | |
Berkshire Hathaway Inc
NYSE:BRK.A
|
US | |
Bank of America Corp
NYSE:BAC
|
US | |
Mastercard Inc
NYSE:MA
|
US | |
UnitedHealth Group Inc
NYSE:UNH
|
US | |
Exxon Mobil Corp
NYSE:XOM
|
US | |
Pfizer Inc
NYSE:PFE
|
US | |
Palantir Technologies Inc
NYSE:PLTR
|
US | |
Nike Inc
NYSE:NKE
|
US | |
Visa Inc
NYSE:V
|
US | |
Alibaba Group Holding Ltd
NYSE:BABA
|
CN | |
3M Co
NYSE:MMM
|
US | |
JPMorgan Chase & Co
NYSE:JPM
|
US | |
Coca-Cola Co
NYSE:KO
|
US | |
Walmart Inc
NYSE:WMT
|
US | |
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.
Diagnos Laboratorium Utama PT Tbk
Cash & Cash Equivalents
Diagnos Laboratorium Utama PT Tbk
Cash & Cash Equivalents Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
Company | Cash & Cash Equivalents | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
---|---|---|---|---|---|---|
D
|
Diagnos Laboratorium Utama PT Tbk
IDX:DGNS
|
Cash & Cash Equivalents
Rp10.2B
|
CAGR 3-Years
-15%
|
CAGR 5-Years
46%
|
CAGR 10-Years
N/A
|
|
Prodia Widyahusada Tbk PT
IDX:PRDA
|
Cash & Cash Equivalents
Rp433.1B
|
CAGR 3-Years
10%
|
CAGR 5-Years
37%
|
CAGR 10-Years
N/A
|
Diagnos Laboratorium Utama PT Tbk
Glance View
PT Diagnos Laboratorium Utama Tbk engages in the provision of health support service. The company employs 54 full-time employees The company went IPO on 2021-01-15. The firm is engaged in providing health support services, such as health laboratories, other diagnostic drawing centers, blood testing laboratories, pharmaceutical warehouses, eye banks, sperm banks and blood banks, organ transplant banks, and other medical support services. The company operates through providing health services using laboratories segment. The Company’s products and services include clinical pathology laboratory, anatomy pathology laboratory, genomic laboratory, homecare health services, corporate health services, and Covid-19 checkup. The firm serves markets, such as Jakarta, Depok, Bali, Bandung, Bekasi, Padang, Makassar, Tangerang Selatan, Dumai, Batam, Purwakarta, Karawang, and Brebes. The company has branch offices in Ciputat (South Tangerang), Denpasar (Bali), Padang (West Sumatra), and Makassar, South Sulawesi.
See Also
What is Diagnos Laboratorium Utama PT Tbk's Cash & Cash Equivalents?
Cash & Cash Equivalents
10.2B
IDR
Based on the financial report for Dec 31, 2023, Diagnos Laboratorium Utama PT Tbk's Cash & Cash Equivalents amounts to 10.2B IDR.
What is Diagnos Laboratorium Utama PT Tbk's Cash & Cash Equivalents growth rate?
Cash & Cash Equivalents CAGR 5Y
46%
Over the last year, the Cash & Cash Equivalents growth was -63%. The average annual Cash & Cash Equivalents growth rates for Diagnos Laboratorium Utama PT Tbk have been -15% over the past three years , 46% over the past five years .